Lyell Immunopharma, Inc. (LYEL) Operating Margin
- Operating margin · 12 months: Value -949981.48%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -949981.48% | Operating income / revenue. Period ending 2026-06-30. $-256.50M ÷ $27.00K × 100 ≈ -949981.48% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -256.50M USD | Operating Income (Loss) |
| Revenue | 27.00K USD | |
| Cost of products and services | (m) | |
| Research and development | (m) | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-256.50M | $27.00K | (m) | (m) | (m) | -949981.48% |
| 2026-03-31 | $-256.30M | $31.00K | (m) | (m) | (m) | -826767.74% |
| 2025-12-31 | $-269.40M | $36.00K | (m) | (m) | (m) | -748344.44% |
| 2025-09-30 | $-342.91M | $41.00K | (m) | (m) | (m) | -836358.54% |
| 2025-06-30 | $-356.16M | $60.00K | (m) | (m) | (m) | -593598.33% |
| 2025-03-31 | $-360.55M | $65.00K | (m) | (m) | (m) | -554687.69% |
| 2024-12-31 | $-358.75M | $61.00K | (m) | (m) | (m) | -588122.95% |
| 2024-09-30 | $-217.12M | $63.00K | (m) | $169.93M | (m) | -344628.57% |
| 2024-06-30 | $-225.65M | $54.00K | (m) | $174.28M | (m) | -417870.37% |
| 2024-03-31 | $-240.03M | $68.00K | (m) | $181.49M | (m) | -352980.88% |
| 2023-12-31 | $-247.01M | $130.00K | (m) | $182.94M | (m) | -190006.15% |
| 2023-09-30 | $-202.28M | $48.50M | (m) | $173.98M | (m) | -417.05% |
| 2023-06-30 | $-209.68M | $48.48M | (m) | $171.74M | (m) | -432.50% |
| 2023-03-31 | $-181.04M | $84.19M | (m) | $167.99M | (m) | -215.02% |
| 2022-12-31 | $-187.06M | $84.68M | (m) | $159.19M | (m) | -220.89% |
| 2022-09-30 | $-219.81M | $39.12M | (m) | $140.44M | (m) | -561.91% |
| 2022-06-30 | $-202.54M | $41.87M | (m) | $130.27M | (m) | -483.71% |
| 2022-03-31 | $-227.98M | $8.76M | (m) | $132.99M | (m) | -2603.13% |
| 2021-12-31 | $-214.78M | $10.65M | (m) | $138.69M | (m) | -2016.68% |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $-211.94M | $7.76M | (m) | $182.24M | (m) | -2732.56% |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $-102.09M | $657.00K | (m) | $63.59M | (m) | -15538.66% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |